Genetics of Menkes Kinky Hair Disease Follow-up
- Author: Stephen G Kaler, MD, MPH; Chief Editor: Bruce Buehler, MD more...
Further Outpatient Care
Several points can be made concerning the general care of patients with Menkes kinky hair disease (MKHD) and their families.
- Genetic counseling is a very important element. As an X-linked recessive trait, the Menkes gene is transmitted by asymptomatic females who are carriers to 50% of their male offspring (who are affected) and to 50% of their female offspring (who are gene carriers). Conversely, 50% of both male and female offspring are healthy. Thus, the overall risk of a child with Menkes kinky hair disease for a woman who is a documented female carrier is 1 in 4 (25%) for each pregnancy (ie, 1 in 2 chance that the sex is male, multiplied times the 1 in 2 chance that the male inherits the Menkes gene). Offer counseling, carrier testing, and, if indicated, prenatal diagnosis to female relatives of a documented gene carrier.
- Concerning pediatric immunizations in infants with Menkes kinky hair disease, no specific contraindications are noted, now that the pertussis component is acellular. Seasonal vaccination against influenza is recommended.
- Prophylaxis against urinary tract infections (eg, Bactrim at 2 mg/kg orally every day) is warranted in patients with bladder diverticula.
- Physical and/or occupational therapy is useful stimulation and can maximize developmental attainment in patients with Menkes kinky hair disease. Such therapy is tailored to the specific child based on his level of neurologic function. Aspects of physical and/or occupational therapy can also be taught to parents for application in the home.
- Menkes kinky hair disease has a substantial emotional impact on the family, and psychosocial support often can be valuable. Just as no health is as vibrant as that of a child, no sickness is as dramatic. Parents of patients with Menkes kinky hair disease often have the pain of watching the transition from apparent good health to essentially irrevocable illness within the first several months of life. Anger, disbelief, guilt, and anxiety regarding an uncertain future are common reactions. Concerning the latter, no reliable way to predict the life span of children with Menkes kinky hair disease is known; however, most of these children die by the time they are aged 3 years. Pneumonia leading to respiratory failure is a common cause of death, although some patients with Menkes kinky hair disease die suddenly in the absence of any acute medical process.
Deterrence/Prevention
- Genetic counseling and prenatal diagnosis (when available and desired) can be helpful in preventing Menkes kinky hair disease. However, an estimated one third of all incidents of Menkes kinky hair disease result from new mutations. Guidelines for prenatal screening and diagnosis have been established.[15]
- Reliable prenatal diagnosis of Menkes kinky hair disease on biochemical grounds has been offered by the John F. Kennedy Institute in Glostrup, Denmark, for nearly 25 years. This testing is indicated for pregnancies in known or suspected female carriers. Carrier status must be suspected in a woman and her female relatives (mother, sisters, daughters) following the diagnosis of Menkes kinky hair disease in a son. Recurrence risk in future pregnancies of such women may be as high as 25%.
- Abnormal egress of radiolabeled copper in cultured amniocytes (reduced compared to normal, ie, a higher percentage of copper retained by cells) was the basis of the original prenatal testing. When techniques for obtaining fetal tissue earlier in gestation (ie, chorionic villus sampling) became available, diagnostic criteria derived from analysis of those tissues were developed (elevated copper content and abnormal copper egress in cultured chorionic cells). In using chorionic villus copper content as the marker, avoiding contamination from the instrument used to obtain the sample or from incomplete separation of the maternal decidua is necessary. The most reliable biochemical marker using chorionic villus specimens has been retention of radiolabeled copper in cultured chorionic cells after a 20-hour pulse and 24-hour chase. Knowledge of the gene for Menkes kinky hair disease enables prenatal testing by molecular means for families in which the proband's mutation has been characterized.
Møller LB, Hicks JD, Holmes CS, Goldstein DS, Brendl C, Huppke P, et al. Diagnosis of copper transport disorders. Curr Protoc Hum Genet. Jul 2011;Chapter 17:Unit17.9. [Medline]. [Full Text].
Kim YH, Lee R, Yoo HW, Yum MS, Bae SH, Chung SC, et al. Identification of a novel mutation in the ATP7A gene in a Korean patient with Menkes disease. J Korean Med Sci. Jul 2011;26(7):951-3. [Medline]. [Full Text].
Datta AK, Ghosh T, Nayak K, Ghosh M. Menkes kinky hair disease: A case report. Cases J. Sep 18 2008;1(1):158. [Medline].
Aldecoa V, Escofet-Soteras C, Artuch R, Ormazabal A, Gabau-Vila E, Martin-Martinez C. [Menkes disease: its clinical, biochemical and molecular diagnosis]. Rev Neurol. Apr 1-15 2008;46(7):446-7. [Medline].
Danks DM, Campbell PE, Walker-Smith J, et al. Menkes' kinky-hair syndrome. Lancet. May 20 1972;1(7760):1100-2. [Medline].
Danks DM, Cartwright E, Stevens BJ, Townley RR. Menkes' kinky hair disease: further definition of the defect in copper transport. Science. Mar 16 1973;179(78):1140-2. [Medline].
Menkes JHM, Alter M, Steigleder GK. A sex-linked recessive disorder with retardation of growth, peculiar hair and focal cerebellar degeneration. Pediatrics. 1962;29:764-769.
Chelly J, Tumer Z, Tonnesen T, et al. Isolation of a candidate gene for Menkes disease that encodes a potential heavy metal binding protein. Nat Genet. Jan 1993;3(1):14-9. [Medline].
Baerlocher K, Nadal D. [Menkes syndrome]. Ergeb Inn Med Kinderheilkd. 1988;57:77-144. [Medline].
Kaler SG. Menkes disease. Adv Pediatr. 1994;41:263-304. [Medline].
Kaler SG, Tang J, Donsante A, Kaneski CR. Translational read-through of a nonsense mutation in ATP7A impacts treatment outcome in Menkes disease. Ann Neurol. Jan 2009;65(1):108-13. [Medline].
Sato R, Okutani K, Higashi T, Satou M, Fujimoto K, Okazaki K. [Case report : respiratory care for anesthesia in a patient with Menkes syndrome and micrognathia]. Masui. Jan 2009;58(1):103-5. [Medline].
Passariello M, Almenrader N, Pietropaoli P. Anesthesia for a child with Menkes disease. Paediatr Anaesth. Dec 2008;18(12):1225-6. [Medline].
Yamashita J, Yamakage M, Kawana S, Namiki A. Two cases of Menkes disease: airway management and dental fragility. Anaesth Intensive Care. Mar 2009;37(2):332-3. [Medline].
[Guideline] Cunniff C. Prenatal screening and diagnosis for pediatricians. Pediatrics. Sep 2004;114(3):889-94. [Medline].
Amaravadi R, Glerum DM, Tzagoloff A. Isolation of a cDNA encoding the human homolog of COX17, a yeast gene essential for mitochondrial copper recruitment. Hum Genet. Mar 1997;99(3):329-33. [Medline].
Bennetts HW, Chapman FE. Copper deficiency in sheep in Western Australia: a preliminary account of the aetiology of enzootic ataxia of lambs and an anemia of ewes. Aust Vet J. 1937;13:138-49.
Camakaris J, Voskoboinik I, Mercer JF. Molecular mechanisms of copper homeostasis. Biochem Biophys Res Commun. Aug 2 1999;261(2):225-32. [Medline].
Francis MJ, Jones EE, Levy ER, et al. A Golgi localization signal identified in the Menkes recombinant protein. Hum Mol Genet. Aug 1998;7(8):1245-52. [Medline].
Grange DK, Kaler SG, Albers GM, et al. Severe bilateral panlobular emphysema and pulmonary arterial hypoplasia: unusual manifestations of Menkes disease. Am J Med Genet A. Dec 1 2005;139(2):151-5. [Medline].
Guitet M, Campistol J, Medina M. [Menkes disease: experience in copper salts therapy]. Rev Neurol. Jul 16-31 1999;29(2):127-30. [Medline].
Kaler SG. Diagnosis and therapy of Menkes syndrome, a genetic form of copper deficiency. Am J Clin Nutr. May 1998;67(5 Suppl):1029S-1034S. [Medline].
Kaler SG. Menkes disease mutations and response to early copper histidine treatment. Nat Genet. May 1996;13(1):21-2. [Medline].
Kaler SG. Metabolic and molecular bases of Menkes disease and occipital horn syndrome. Pediatr Dev Pathol. Jan-Feb 1998;1(1):85-98. [Medline].
Kaler SG, Buist NR, Holmes CS, et al. Early copper therapy in classic Menkes disease patients with a novel splicing mutation. Ann Neurol. Dec 1995;38(6):921-8. [Medline].
Kaler SG, Das S, Levinson B, et al. Successful early copper therapy in menkes disease associated with a mutant transcript containing a small In-frame deletion. Biochem Mol Med. Feb 1996;57(1):37-46. [Medline].
Kaler SG, Gahl WA, Berry SA, et al. Predictive value of plasma catecholamine levels in neonatal detection of Menkes disease. J Inherit Metab Dis. 1993;16(5):907-8. [Medline].
Kaler SG, Gallo LK, Proud VK, et al. Occipital horn syndrome and a mild Menkes phenotype associated with splice site mutations at the MNK locus. Nat Genet. Oct 1994;8(2):195-202. [Medline].
Kaler SG, Goldstein DS, Holmes C, et al. Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease. Ann Neurol. Feb 1993;33(2):171-5. [Medline].
Kaler SG, Schwartz JP. Expression of the Menkes disease homolog in rodent neuroglial cells. Neurosci Res Commun. 1998;23:61-66.
Kaler SG, Tumer Z. Prenatal diagnosis of Menkes disease. Prenat Diagn. Mar 1998;18(3):287-9. [Medline].
Klomp LW, Lin SJ, Yuan DS et al. Identification and functional expression of HAH1, a novel human gene involved in copper homeostasis. J Biol Chem. Apr 4 1997;272(14):9221-6. [Medline].
Kodama H, Murata Y, Kobayashi M. Clinical manifestations and treatment of Menkes disease and its variants. Pediatr Int. Aug 1999;41(4):423-9. [Medline].
La Fontaine SL, Firth SD, Camakaris J, et al. Correction of the copper transport defect of Menkes patient fibroblasts by expression of the Menkes and Wilson ATPases. J Biol Chem. Nov 20 1998;273(47):31375-80. [Medline].
Levinson B, Conant R, Schnur R, et al. A repeated element in the regulatory region of the MNK gene and its deletion in a patient with occipital horn syndrome. Hum Mol Genet. Nov 1996;5(11):1737-42. [Medline].
Mercer JF, Livingston J, Hall B, et al. Isolation of a partial candidate gene for Menkes disease by positional cloning. Nat Genet. Jan 1993;3(1):20-5. [Medline].
Moller LB, Tumer Z, Lund C, et al. Similar splice-site mutations of the ATP7A gene lead to different phenotypes: classical Menkes disease or occipital horn syndrome. Am J Hum Genet. Apr 2000;66(4):1211-20. [Medline].
Payne AS, Gitlin JD. Functional expression of the menkes disease protein reveals common biochemical mechanisms among the copper-transporting P-type ATPases. J Biol Chem. Feb 6 1998;273(6):3765-70. [Medline].
Petris MJ, Mercer JF. The Menkes protein (ATP7A; MNK) cycles via the plasma membrane both in basal and elevated extracellular copper using a C-terminal di-leucine endocytic signal. Hum Mol Genet. Oct 1999;8(11):2107-15. [Medline].
Petris MJ, Mercer JF, Camakaris J. The cell biology of the Menkes disease protein. Adv Exp Med Biol. 1999;448:53-66. [Medline].
Petris MJ, Strausak D, Mercer JF. The Menkes copper transporter is required for the activation of tyrosinase. Hum Mol Genet. Nov 22 2000;9(19):2845-51. [Medline].
Prohaska JR, Tamura T, Percy AK, Turnlund JR. In vitro copper stimulation of plasma peptidylglycine alpha-amidating monooxygenase in Menkes disease variant with occipital horns. Pediatr Res. Dec 1997;42(6):862-5. [Medline].
Pufahl RA, Singer CP, Peariso KL, et al. Metal ion chaperone function of the soluble Cu(I) receptor Atx1. Science. Oct 31 1997;278(5339):853-6. [Medline].
Robertson D, Goldberg MR, Onrot J, et al. Isolated failure of autonomic noradrenergic neurotransmission. Evidence for impaired beta-hydroxylation of dopamine. N Engl J Med. Jun 5 1986;314(23):1494-7. [Medline].
Sarkar B, Lingertat-Walsh K, Clarke JT. Copper-histidine therapy for Menkes disease. J Pediatr. Nov 1993;123(5):828-30. [Medline].
Schaefer M, Gitlin JD. Genetic disorders of membrane transport. IV. Wilson's disease and Menkes disease. Am J Physiol. Feb 1999;276(2 Pt 1):G311-4. [Medline].
Sheela SR, Latha M, Liu P, et al. Copper-replacement treatment for symptomatic Menkes disease: ethical considerations. Clin Genet. Sep 2005;68(3):278-83. [Medline].
Suzuki M, Gitlin JD. Intracellular localization of the Menkes and Wilson's disease proteins and their role in intracellular copper transport. Pediatr Int. Aug 1999;41(4):436-42. [Medline].
Tumer Z, Horn N, Tonnesen T, et al. Early copper-histidine treatment for Menkes disease. Nat Genet. Jan 1996;12(1):11-3. [Medline].
Tumer Z, Lund C, Tolshave J, et al. Identification of point mutations in 41 unrelated patients affected with Menkes disease. Am J Hum Genet. Jan 1997;60(1):63-71. [Medline].
Tumer Z, Moller LB, Horn N. Mutation spectrum of ATP7A, the gene defective in Menkes disease. Adv Exp Med Biol. 1999;448:83-95. [Medline].
Valentine JS, Gralla EB. Delivering copper inside yeast and human cells. Science. Oct 31 1997;278(5339):817-8. [Medline].
Voskoboinik I, Strausak D, Greenough M, et al. Functional analysis of the N-terminal CXXC metal-binding motifs in the human menkes copper-transporting P-type ATPase expressed in cultured mammalian cells. J Biol Chem. Jul 30 1999;274(31):22008-12. [Medline].
Vulpe C, Levinson B, Whitney S, et al. Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper-transporting ATPase. Nat Genet. Jan 1993;3(1):7-13. [Medline].

